NIH SBIR Bioethics Research Funding for Startups: 2026 Guide

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Quick Answer

The NIH Highlighted Topic "Strengthening Biomedical Research, Promoting Trust, and Improving Health through Bioethics Research" invites small businesses to develop actionable bioethics tools and approaches across artificial intelligence, research engagement, informed consent, and return of research results. This is not a standalone funding opportunity. It is a Highlighted Topic, which means you apply through the NIH, CDC and FDA Parent SBIR announcement (PA-27-100) or, if you are partnering with a university or other nonprofit, the Parent STTR announcement (PA-27-102). The topic is active from August 14, 2026 through January 12, 2028. Standard NIH SBIR due dates are September 5, 2026 (adjusted to September 8, 2026), January 5, 2027, and April 5, 2027. Phase I funding runs up to the current SBA guideline of about $323,090, with several participating Institutes offering waivers of $400,000 or $700,000. Phase II funding runs up to about $2,153,927 under the SBA guideline, with several Institutes offering waivers of $2.5 million or $3 million.

What Is the NIH Bioethics Research Highlighted Topic?

The Highlighted Topic is an area of science that NIH has flagged as a priority for its participating Institutes, Centers, and Offices. It signals to investigators that if they build a competitive application in this space, multiple NIH components are interested in funding it. A Highlighted Topic is not a Notice of Funding Opportunity. There is no separate application package, no dedicated funding number, and no set-aside budget attached to the topic itself. Instead, NIH directs you to submit through a broad parent announcement and to make your project relevant to at least one participating Institute or Center that awards grants.

For a small business, the practical path is the Parent SBIR announcement PA-27-100. If your project depends on a formal collaboration with a nonprofit research institution such as a university, the correct vehicle is the Parent STTR announcement PA-27-102. In both programs the award goes to the small business, and both are strong fits for bioethics work because much of the field's expertise sits inside academic centers.

The topic was posted on August 14, 2026 and expires January 12, 2028. Because that window spans more than a year, you can target any of the standard SBIR due dates that fall inside it, applying through whichever parent SBIR announcement is current at your chosen deadline.

How Do You Apply for This Bioethics Topic?

You apply by submitting an SBIR application to PA-27-100 (or an STTR application to PA-27-102) and making your project responsive to the bioethics areas of interest for at least one participating Institute or Center. You do not apply to the Highlighted Topic directly.

A few practical points shape a competitive submission. First, NIH's Center for Scientific Review assigns every application to the most appropriate Institute, so you are not required to name an awarding component in advance. You may request an assignment on the PHS Assignment Request Form, and you are strongly encouraged to contact program staff at the Institute you believe is the best fit before you apply. Second, several of the offices listed in the topic, including the Office of Science Policy, the Office of AIDS Research, the Office of Behavioral and Social Sciences Research, and the Office of Data Science Strategy, do not award grants. Your application must map to an Institute or Center that does. Third, because SBIR is a commercialization program, your bioethics work needs a product or service with commercial potential, not a purely academic study. More on that below.

What Kind of Research Is NIH Looking For?

The purpose of this topic is to advance bioethics research projects that are actionable, that build trust, and that improve how bioethical principles are integrated into biomedical and behavioral research. NIH wants work that strengthens science so that research generates evidence-based products communities will adopt more readily. The specific areas of interest fall into five buckets.

Artificial intelligence. NIH is interested in access to and use of AI models and algorithms, maximizing the generalizability of AI, strategies for AI transparency and data privacy, and the integration of digital health research. This is one of the most naturally commercializable areas for a startup, covering audit and transparency tooling, bias and generalizability testing, and privacy-preserving infrastructure.

Research engagement. NIH is interested in approaches for effective community engagement, co-developing research priorities with communities, building and sustaining research trustworthiness, and improving recruitment and access to clinical trials. Platforms and methods that make engagement measurable and repeatable are a fit here.

Informed consent. NIH is interested in strategies and structures for facilitating transparency and autonomy, community approaches to consenting for population-level public health research, and novel forms of consent, including consent for research use of electronic health records, wearables, linked data, and public health data. Consent management systems and dynamic consent tooling map directly to this area.

Return of research results. NIH is interested in approaches for returning aggregate and individual research results, strategies for communicating findings in ways that support health decision-making, and considerations for populations with unique needs or decision-making circumstances. Communication tools and result-delivery systems fit here.

Other cross-cutting issues. NIH also flags data access and sharing, biosafety and biosecurity, and emerging and novel technologies.

Individual Institutes layer their own priorities on top of these buckets. The National Human Genome Research Institute is focused on ethical, legal, and social implications of genetics and genomics. The National Institute of Biomedical Imaging and Bioengineering is focused on ethics across the technology development continuum, including AI and machine learning, point-of-care technologies, and re-identifiability risks from imaging data. The National Institute on Aging is focused on autonomy, consent tailored to older adults, and the ethical use of AI in aging populations. The National Institute on Drug Abuse is focused on return of results, stigma reduction, and vulnerable-population protections. The BRAIN Initiative, the National Institute of Neurological Disorders and Stroke, and the National Eye Institute each bring neurotechnology, neuroimaging, and vision-specific angles. Aligning your project to a specific Institute's stated priorities, rather than to the topic in general, is what separates a fundable application from a vague one.

Which NIH Institutes and Centers Participate?

The Institutes and Centers that award grants under this topic include the National Cancer Institute, the National Eye Institute, the National Human Genome Research Institute, the National Heart, Lung, and Blood Institute, the National Institute on Aging, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Allergy and Infectious Diseases, the National Institute of Biomedical Imaging and Bioengineering, the National Institute on Drug Abuse, the National Institute on Deafness and Other Communication Disorders, the National Institute of Dental and Craniofacial Research, the National Institute of Environmental Health Sciences, the National Institute of Mental Health, the National Institute of Neurological Disorders and Stroke, and the National Institute of Nursing Research. The BRAIN Initiative also participates, funding through its associated Institutes.

Several offices are interested in the topic but do not award grants, including the Office of Science Policy, the Office of AIDS Research, the Office of Behavioral and Social Sciences Research, and the Office of Data Science Strategy. Applications relevant to these offices must still be assigned to and funded by one of the participating grant-making Institutes or Centers.

How Much Funding Can a Startup Receive?

Funding depends on which Institute your application is assigned to, because budgets vary across NIH components. The default ceiling is the current SBA guideline, which NIH lists at about $323,090 in total costs for Phase I and about $2,153,927 for Phase II. Those figures include direct costs, indirect costs, and fee, and the SBA adjusts them annually, so confirm the current number on the NIH SEED website before you build your budget.

Many Institutes have secured waivers to exceed the SBA guideline. Among the components participating in this bioethics topic, the following Phase I ceilings apply. The National Cancer Institute, the National Institute on Aging, the National Institute of Allergy and Infectious Diseases, the National Institute of Mental Health, and the National Institute of Neurological Disorders and Stroke offer Phase I budgets up to $700,000. The National Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Drug Abuse, the National Institute on Deafness and Other Communication Disorders, and the National Institute of Nursing Research offer Phase I budgets up to $400,000. The National Eye Institute and the National Human Genome Research Institute set Phase I at $400,000. The National Institute of Biomedical Imaging and Bioengineering, the National Institute of Dental and Craniofacial Research, and the National Institute of Environmental Health Sciences follow the standard SBA guideline for Phase I.

On the Phase II side, the National Heart, Lung, and Blood Institute, the National Institute on Aging, the National Institute of Allergy and Infectious Diseases, the National Institute on Drug Abuse, the National Institute on Deafness and Other Communication Disorders, the National Institute of Mental Health, and the National Institute of Neurological Disorders and Stroke offer Phase II budgets up to $3 million. The National Cancer Institute, the National Institute on Alcohol Abuse and Alcoholism, and the National Institute of Nursing Research offer Phase II budgets up to $2.5 million. The National Eye Institute, the National Human Genome Research Institute, the National Institute of Biomedical Imaging and Bioengineering, the National Institute of Dental and Craniofacial Research, and the National Institute of Environmental Health Sciences follow the standard SBA guideline for Phase II.

In every case, NIH expects a budget that is reasonable and appropriate for the work, not a number anchored to the ceiling. Requests at or near a hard cap should be well justified. If you intend to request more than the SBA guideline, contact the participating Institute early in your planning process.

What Is the Timeline and What Are the Deadlines?

The Parent SBIR announcement opened for submissions on August 5, 2026. Its standard due dates are September 5, 2026, January 5, 2027, and April 5, 2027, each at 5:00 PM local time of the applicant organization. When a due date falls on a weekend or federal holiday, NIH automatically rolls it to the next business day. September 5, 2026 is a Saturday and September 7 is Labor Day, so the effective first deadline is Tuesday, September 8, 2026. The Parent SBIR announcement PA-27-100 itself expires April 6, 2027, and NIH typically reissues its parent announcements, so applicants targeting later cycles should apply through whichever parent SBIR is current at that time.

The review path is predictable. An application submitted for the September 2026 cycle receives scientific merit review in November 2026, advisory council review in January 2027, and an earliest possible start date of April 2027. A January 2027 submission maps to March 2027 review, May 2027 council, and a July 2027 earliest start. Build backward from your target start date, and remember that no late applications are accepted for this announcement.

Project periods are constrained by statute. Phase I awards normally may not exceed 6 months, and Phase II awards normally may not exceed 2 years. NIH also offers two accelerated paths that only apply to NIH components: Fast-Track, which submits and reviews Phase I and Phase II together to reduce the funding gap, and Direct to Phase II, for companies that have already demonstrated feasibility but never received a Phase I for that project.

Who Is Eligible to Apply?

Only United States small business concerns are eligible. To qualify, your company must be organized for profit with a place of business in the United States, must operate primarily in the United States or make a significant contribution to the US economy, and must have no more than 500 employees including affiliates. Ownership must satisfy one of the allowed structures: more than 50 percent directly owned and controlled by US citizens or permanent residents, or majority owned by multiple venture capital operating companies, hedge funds, or private equity firms under the specific limits in the announcement, where no single such firm owns more than 50 percent unless it independently qualifies as a small business.

The Program Director or Principal Investigator must be primarily employed by the small business at the time of award and during the project. For projects with multiple PDs or PIs, at least one must meet this primary employment requirement.

The work-share rules also matter. In SBIR Phase I, the small business normally performs at least two-thirds, or 67 percent, of the research or analytical effort. In SBIR Phase II, the small business normally performs at least one-half, or 50 percent. Consultant and contractual arrangements to third parties are generally capped at the remaining share. If your bioethics project leans heavily on academic collaborators, the STTR announcement PA-27-102 may be the better structural fit, since it allows a nonprofit partner to perform a larger share.

What Registrations Do You Need Before Applying?

You must complete and maintain several registrations before you can submit, and they can take six weeks or more in total, so start immediately. You need an active System for Award Management registration, which issues your Unique Entity Identifier and a CAGE Code. You need to register in the SBA Company Registry, which requires your UEI first. You need an eRA Commons account for your organization, with at least one Signing Official and one Program Director or Principal Investigator, and obtaining an account can take up to two weeks. You need a Grants.gov registration, which depends on an active SAM registration. Every PD or PI must also have an eRA Commons ID and must link a valid ORCID iD to their eRA Commons profile. Failure to complete registrations on time is not an accepted reason for a late submission.

What Are the Key Compliance and Foreign Risk Rules?

Two areas deserve early attention. The first is foreign involvement. Non-US entities and non-US components of US organizations are not eligible to apply. NIH will not issue awards that involve foreign subawards or subcontracts under this announcement, and any application that includes them will be deemed noncompliant and will not be funded. Unfunded international collaborations, funding for foreign consultants, and procurement of unique equipment or supplies from foreign vendors may still be allowed.

The second is foreign risk disclosure and security review. Applicants under consideration for award must submit the SBA Required Disclosures of Foreign Affiliations or Relationships to Foreign Countries form during the just-in-time process, covering all owners and covered individuals. HHS cannot make an award if the company has an owner or covered individual party to a malign foreign talent recruitment program, a parent company or subsidiary located in the People's Republic of China or another country of concern, or other disqualifying ties described in the announcement. NIH, CDC, and FDA will not provide an opportunity to cure an identified security risk before award, though a denial on security grounds does not bar the company from applying in a later cycle.

A few additional terms are worth knowing. This announcement is clinical trial optional, but some Institutes do not accept clinical trials, so confirm your target component accepts your study design. SBIR recipients may retain data rights for up to 20 years after the award date. Cost sharing is not required.

How Should a Startup Frame a Bioethics Project for SBIR?

This is the point most applicants miss. SBIR is a commercialization program, not a research grant program in the traditional academic sense. Reviewers score significance, investigators, innovation, approach, and environment, and for Phase II and Fast-Track they weigh a Commercialization Plan heavily. A bioethics project that reads like a scholarly study will struggle. A bioethics project framed as a product or service with a clear market, clear customers, and a clear path to revenue will compete.

The most commercializable angles in this topic are the ones that produce software, tooling, or repeatable methods. Examples include AI transparency, audit, and generalizability testing tools; privacy-preserving data infrastructure and de-identification systems; dynamic and electronic consent management platforms, including consent for wearables, EHR data, and linked datasets; community engagement platforms that make trust-building measurable; and return-of-results communication systems tailored to specific populations. If you can name the customer who would pay for your solution and explain how it solves a demonstrated need, you have the spine of a competitive application. If you cannot, the project may be better suited to a non-SBIR mechanism.

How BW&CO Helps

BW&CO helps deep-tech, health, and AI founders match their technology to the right NIH Institute, choose between the SBIR and STTR routes, structure a fundable budget within the correct ceiling, and build the commercialization narrative that NIH reviewers reward. If you are evaluating whether your product fits this bioethics topic, or which of the participating Institutes is the strongest home for your work, we can help you make that call before you invest in a full application.

Frequently Asked Questions

Is the NIH Bioethics Research topic a funding opportunity you can apply to directly?

No. It is a Highlighted Topic, not a Notice of Funding Opportunity. There is no separate application package or funding number. You apply through the NIH Parent SBIR announcement PA-27-100, or the Parent STTR announcement PA-27-102 if you are partnering with a nonprofit research institution, and you make your project responsive to at least one participating Institute or Center.

What is the deadline to apply?

The standard NIH SBIR due dates are September 5, 2026, January 5, 2027, and April 5, 2027, at 5:00 PM local time of the applicant organization. Because September 5, 2026 is a Saturday and September 7 is Labor Day, the effective first deadline is September 8, 2026. The Highlighted Topic remains active through January 12, 2028.

How much SBIR funding can my startup receive?

Phase I runs up to the current SBA guideline of about $323,090, with several participating Institutes offering waivers of $400,000 or $700,000. Phase II runs up to about $2,153,927 under the SBA guideline, with several Institutes offering waivers of $2.5 million or $3 million. The exact ceiling depends on which Institute your application is assigned to.

Who is eligible to apply?

United States small business concerns that are for-profit, have no more than 500 employees including affiliates, meet the ownership rules, and whose Program Director or Principal Investigator is primarily employed by the company at the time of award.

Can universities apply for this topic?

No. The award goes to the small business. A university can participate as a partner through the STTR announcement PA-27-102, or as a subaward or consultant within the SBIR work-share limits, which allow up to about one-third of the effort to third parties in Phase I and up to about one-half in Phase II.

Does my bioethics project need a commercial product?

Yes. SBIR is a commercialization program, so your project needs a product or service with commercial potential and a credible path to market. The strongest fits produce software, tooling, or repeatable methods, such as AI transparency tools, consent management platforms, or return-of-results communication systems.

Which NIH Institutes fund this topic?

Participating grant-making components include NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIBIB, NIDA, NIDCD, NIDCR, NIEHS, NIMH, NINDS, and NINR, along with the BRAIN Initiative. Several offices are interested but do not award grants, so applications must be assigned to a grant-making Institute or Center.

Do I need to pick an Institute before I apply?

No. NIH's Center for Scientific Review assigns your application to the most appropriate component. You may request an assignment on the PHS Assignment Request Form, and you are strongly encouraged to contact program staff at your target Institute before submitting.

How long does registration take?

Plan for six weeks or more. You need active registrations in SAM, the SBA Company Registry, eRA Commons, and Grants.gov, and each PD or PI needs an eRA Commons ID linked to an ORCID iD. Late registration is not an accepted reason for a late submission.

Can foreign companies or foreign subawards be involved?

No. Only US small business concerns are eligible, and applications that include foreign subawards or subcontracts are deemed noncompliant and will not be funded. Unfunded international collaborations, foreign consultants, and procurement of unique equipment or supplies from foreign vendors may still be permitted.